Quest Diagnostics has rolled out an ultrasensitive blood test to monitor multiple myeloma treatment, potentially sparing ...
Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the launch of a novel ...
Dr Mark Kris discusses the increasing precision of lung cancer therapies and the need for additional testing to find ...
Quest Diagnostics has introduced a new flow cytometry MRD blood test for myeloma, a cancer arising from abnormal plasma cells.
Gene Solutions, a global biotechnology company, and Pangea Laboratory, a CLIA-certified, CAP-accredited Next Generation Sequencing (NGS) leader in validation platforms for Laboratory Developed Tests ...
Biomarker testing is crucial for personalized oncology care, aiding in risk stratification and treatment decisions, but faces ...
"Clinicians performing tumor biopsy need to ensure that there’s adequate tissue for both diagnosis and NGS testing. Having immediate pathology review of biopsy specimens in the operating room can ...
Pathological analysis of tumor microenvironmental features using deep learning to predict survival of colon carcinomas. A prospective, cross-sectional, multicentre study to evaluate the clinical ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Universal DX (“UDX”), a biotech company dedicated to transforming cancer into a curable disease by detecting it early, today announced closure of the Series B which ...
Precision medicine in endometrial cancer emphasizes molecular drivers, challenging traditional histopathologic approaches and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results